BioSpace News Archive

Omeza, a skin science company, announced today the U.S. Food and Drug Administration (FDA) cleared Omeza® Collagen Matrix through the FDA 510(k) premarket notification process

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, reported results for its fiscal year ended June 30, 2021.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will participate in four upcoming investor conferences.

Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2021.

Hologic, Inc. announced that the Company will present at these upcoming virtual investor conferences.

Amphastar Pharmaceuticals, Inc. announced that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will be presenting at the Wells Fargo 2021 Virtual Healthcare Conference on Thursday, September 9, 2021, at 2:00 pm Eastern time.

Arcutis Biotherapeutics, Inc. announced that Keith R. Leonard Jr. has been appointed to the Arcutis Board of Directors effective September 2, 2021, replacing Ricky Sun, Ph.D., who has decided to step down from the Board for personal reasons.

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced that the Company will participate in two upcoming virtual investor conferences.

Pulse Biosciences, Inc., a novel bioelectric medicine company introducing the CellFX® System powered by Nano-Pulse Stimulation™ technology, announced plans to participate in the upcoming virtual H.C. Wainwright Global Investment Conference.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 43,000 shares of KalVista common stock on September 1, 2021 as inducements material to each employee entering into employment with KalVista.